| 000 | 05643nam a22004215i 4500 | ||
|---|---|---|---|
| 001 | 978-0-387-27080-7 | ||
| 003 | DE-He213 | ||
| 005 | 20250710083937.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 100301s2005 xxu| s |||| 0|eng d | ||
| 020 |
_a9780387270807 _a99780387270807 |
||
| 024 | 7 |
_a10.1007/b138566 _2doi |
|
| 082 | 0 | 4 |
_a519.5 _223 |
| 100 | 1 |
_aBurzykowski, Tomasz. _eeditor. |
|
| 245 | 1 | 4 |
_aThe Evaluation of Surrogate Endpoints _h[recurso electrónico] / _cedited by Tomasz Burzykowski, Geert Molenberghs, Marc Buyse. |
| 264 | 1 |
_aNew York, NY : _bSpringer New York, _c2005. |
|
| 300 |
_aXXIV, 408 p. 57 illus. _bonline resource. |
||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_arecurso en línea _bcr _2rdacarrier |
||
| 347 |
_atext file _bPDF _2rda |
||
| 490 | 1 |
_aStatistics for Biology and Health, _x1431-8776 |
|
| 505 | 0 | _aSetting the Scene -- Regulatory Aspects in Using Surrogate Markers in Clinical Trials -- Notation and Motivating Studies -- The History of Surrogate Endpoint Validation -- Validation Using Single-trial Data: Mixed Binary and Continuous Outcomes -- A Meta-analytic Validation Framework for Continuous Outcomes -- The Choice of Units -- Extensions of the Meta-analytic Approach to Surrogate Endpoints -- Meta-analytic Validation with Binary Outcomes -- Validation in the Case of Two Failure-time Endpoints -- An Ordinal Surrogate for a Survival True Endpoint -- A Combination of Longitudinal and Survival Endpoints -- Repeated Measures and Surrogate Endpoint Validation -- Bayesian Evaluation of Surrogate Endpoints -- Surrogate Marker Validation in Mental Health -- The Evaluation of Surrogate Endpoints in Practice: Experience in HIV -- An Alternative Measure for Meta-analytic Surrogate Endpoint Validation -- Discussion: Surrogate Endpoint Definition and Evaluation -- The Promise and Peril of Surrogate Endpoints in Cancer Research. | |
| 520 | _aBoth humanitarian and commercial considerations have spurred intensive search for methods to reduce the time and cost required to develop new therapies. The identification and use of surrogate endpoints, i.e., measures that can replace or supplement other endpoints in evaluations of experimental treatments or other interventions, is a general strategy that has stimulated both enthusiasm and skepticism. Surrogate endpoints are useful when they can be measured earlier, more conveniently, or more frequently than the "true" endpoints of primary interest. Regulatory agencies around the globe, particularly in the United States, Europe, and Japan, are introducing provisions and policies relating to the use of surrogate endpoints in registration studies. But how can one establish the adequacy of a surrogate? What kind of evidence is needed, and what statistical methods portray that evidence most appropriately? This book offers a balanced account on this controversial topic. The text presents major developments of the last couple of decades, together with a unified, meta-analytic framework within which surrogates can be evaluated from several angles. Methodological development is coupled with perspectives on various therapeutic areas. Academic views are juxtaposed with standpoints of scientists working in the biopharmaceutical industry as well as of colleagues from the regulatory authorities. Tomasz Burzykowski is Assistant Professor of Biostatistics at the Limburgs Universitair Centrum in Belgium. Dr. Burzykowski has published methodological work on the analysis of survey data, meta-analyses of clinical trials, and validation of surrogate endpoints. He is a co-author of numerous papers applying statistical methods to clinical data in different disease areas (cancer, cardiovascular diseases, dermatology, orthodontics). Geert Molenberghs is Professor of Biostatistics at the Limburgs Universitair Centrum in Belgium. Dr. Molenberghs published methodological work on surrogate markers in clinical trials, categorical data, longitudinal data analysis, and on the analysis of non-response in clinical and epidemiological studies. He serves as Joint Editor for Applied Statistics (2001-2004) and is President of the International Biometric Society (2004-2005). He was elected Fellow of the American Statistical Association and received the Guy Medal in Bronze from the Royal Statistical Society. Marc Buyse founded the International Drug Development Institute in 1991. He is Past President of the International Society for Clinical Biostatistics, Past President of the Quetelet Society, and Past Board Member of the Society for Clinical Trials. He is currently the Executive Director of IDDI (International Drug Development Institute) and Associate Professor of biostatistics at the Limburgs Universitair Centrum, Center for Statistics, Diepenbeek, Belgium. He has published extensively in the fields of biostatistics and oncology. His research interests include meta-analysis, surrogate endpoints, statistical detection of fraud, and the design and statistical analysis of clinical trials. | ||
| 650 | 0 | _aSTATISTICS. | |
| 650 | 1 | 4 | _aSTATISTICS. |
| 650 | 2 | 4 | _aSTATISTICS FOR LIFE SCIENCES, MEDICINE, HEALTH SCIENCES. |
| 700 | 1 |
_aMolenberghs, Geert. _eeditor. |
|
| 700 | 1 |
_aBuyse, Marc. _eeditor. |
|
| 710 | 2 | _aSpringerLink (Online service) | |
| 773 | 0 | _tSpringer eBooks | |
| 776 | 0 | 8 |
_iPrinted edition: _z9780387202778 |
| 830 | 0 |
_aStatistics for Biology and Health, _x1431-8776 |
|
| 856 | 4 | 0 |
_uhttp://dx.doi.org/10.1007/b138566 _zVer el texto completo en las instalaciones del CICY |
| 912 | _aZDB-2-SMA | ||
| 942 |
_2ddc _cER |
||
| 999 |
_c56617 _d56617 |
||